Literature DB >> 25496960

Lung adenocarcinoma harboring concomitant EGFR mutation and EML4-ALK fusion that benefits from three kinds of tyrosine kinase inhibitors: a case report and literature review.

Ning Zhao1, Shu-yi Zheng2, Jin-ji Yang1, Xu-chao Zhang1, Zhi Xie1, Bin Xie3, Jian Su1, Zhi-hong Chen1, Shi-liang Chen1, Na Zhang1, Na-na Lou1, Song Dong1, Yi-long Wu4.   

Abstract

Entities:  

Keywords:  Concomitant; Echinoderm microtubule-associated protein-like 4; Epidermal growth factor receptor; NSCLC; Tyrosine kinase inhibitor

Mesh：

Substances：

Year:  2014        PMID： 25496960     DOI： 10.1016/j.cllc.2014.11.001

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  11 in total

Review 1.  Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.

Authors:  Richard Bayliss; Jene Choi; Dean A Fennell; Andrew M Fry; Mark W Richards
Journal:  Cell Mol Life Sci       Date:  2016-01-11       Impact factor: 9.261

2.  Metastatic EML4-ALK fusion detected by circulating DNA genotyping in an EGFR-mutated NSCLC patient and successful management by adding ALK inhibitors: a case report.

Authors:  Wenhua Liang; Qihua He; Ying Chen; Shaokun Chuai; Weiqiang Yin; Wei Wang; Guilin Peng; Caicun Zhou; Jianxing He
Journal:  BMC Cancer       Date:  2016-02-05       Impact factor: 4.430

3.  Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant EGFR mutation and ALK gene rearrangement: A case report and review of the literature.

Authors:  Yuping Li; Shanshan Su; Guoping Cai; Quan Lin; Ying Zhou; Jinsheng Ouyang; Bicheng Chen; Junru Ye; Xiuling Wu; Chengshui Chen
Journal:  Mol Clin Oncol       Date:  2017-06-29

Review 4.  Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases.

Authors:  Giuseppe Lo Russo; Martina Imbimbo; Giulia Corrao; Claudia Proto; Diego Signorelli; Milena Vitali; Monica Ganzinelli; Laura Botta; Nicoletta Zilembo; Filippo de Braud; Marina Chiara Garassino
Journal:  Oncotarget       Date:  2017-04-26

5.  Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics.

Authors:  Ilija Nenadić; Jeanine Staber; Susanne Dreier; Guus Simons; Verena Schildgen; Michael Brockmann; Oliver Schildgen
Journal:  Cancers (Basel)       Date:  2017-07-11       Impact factor: 6.639

6.  Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.

Authors:  Na-Na Lou; Xu-Chao Zhang; Hua-Jun Chen; Qing Zhou; Li-Xu Yan; Zhi Xie; Jian Su; Zhi-Hong Chen; Hai-Yan Tu; Hong-Hong Yan; Zhen Wang; Chong-Rui Xu; Ben-Yuan Jiang; Bin-Chao Wang; Xiao-Yan Bai; Wen-Zhao Zhong; Yi-Long Wu; Jin-Ji Yang
Journal:  Oncotarget       Date:  2016-10-04

7.  Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib.

Authors:  Akira Yokoyama; Atsuhisa Tamura; Kazuko Miyakawa; Kei Kusaka; Masahiro Shimada; Takashi Hirose; Hirotoshi Matsui; Masashi Kitani; Akira Hebisawa; Ken Ohta
Journal:  Intern Med       Date:  2018-03-09       Impact factor: 1.271

8.  Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.

Authors:  Xiaoyun Zhou; Jiawei Shou; Jin Sheng; Chunwei Xu; Shengxiang Ren; Xiuyu Cai; Qian Chu; Wenxian Wang; Qinhong Zhen; Yuefen Zhou; Wenfeng Li; Hong Pan; Hongsen Li; Tao Sun; Huanqing Cheng; Huina Wang; Feng Lou; Chuangzhou Rao; Shanbo Cao; Hongming Pan; Yong Fang
Journal:  Cancer Sci       Date:  2019-09-23       Impact factor: 6.716

9.  Synchronous Presence of EGFR, ALK Driver Mutations Along With PD L1 Overexpression in a Resected Early Stage Non-Small Cell Lung Cancer: A Case Report and Review of Literature.

Authors:  Nishitha Thumallapally; Sara Parylo; Adarsh Vennepureddy; Uroosa Ibrahim; Alisa Sokoloff
Journal:  World J Oncol       Date:  2018-05-01

10.  [Advances in Double Mutations of EGFR and ALK Gene in Non-small Cell Lung Cancer].

Authors:  Xin Wang; Diansheng Zhong
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2018-09-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.